Agendia is committed to improving clinical outcomes and informing the journey for patients with early stage breast cancer. MammaPrint®, the 70-gene breast cancer recurrence assay, is the first FDA-cleared risk-of-recurrence test backed by peer-reviewed, prospective outcome data and included in both national and international guidelines. BluePrint®, the 80-gene molecular subtyping assay, evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make informed treatment decisions. Agendia’s assays can be ordered on core biopsies or surgical specimens with results in as little as 5-7 days to inform pre- and post-operative treatment decisions. Learn more: www.agendia.com
Brands: https://events.jspargo.com/ASCO21/CUSTOM/Agendia%20ASCO%20Booth%20Banner%20(1)%20(002).png
Show Specials
Press Releases
Products